CoChat

CTLA-4 (CD152): A versatile receptor for immune-based therapy

Lingel, Holger, Brunner-Weinzierl, Monika C. · 2019 · Seminars in Immunology
Cited by 80

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Coreceptor-based immunotherapy is a rapidly developing approach to treat cancer patients. Among those targeted receptors, CTLA-4 is the primary attenuator of adaptive immune responses and the most prominent and extensively investigated molecule in this field. CTLA-4 is involved in broad range of mechanisms that regulate and control immune cell functions and therefore provides versatile strategies for therapeutic interventions. Despite being successfully harnessed in clinical treatments the different facets of CTLA-4 biology still remain incompletely understood. Here, we review the various aspects of CTLA-4 functions and CTLA-4-based immunotherapies and discuss challenges to improve current approaches.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.smim.2019.101298

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 80

Metadata

Authors
Lingel, H., & Brunner-Weinzierl, M. C.
Venue
Seminars in Immunology
Publisher
Elsevier BV
Published
2019-04
Volume
42
Pages
101298
ISSN
1044-5323 (ISSN-L)
OpenAlex
W2979770544
Cited by
80
References
32
FWCI
2.27
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CTLA-4 (CD152): A versatile receptor for immune-based therapy. https://app.cochat.ai/papers/10.1016/j.smim.2019.101298
The paper
Lingel, H., & Brunner-Weinzierl, M. C. (2019). CTLA-4 (CD152): A versatile receptor for immune-based therapy. Seminars in Immunology. https://doi.org/10.1016/j.smim.2019.101298

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.